956034-07-4

Basic information

• Product Name: 2,4-DICHLOROFURO[3,2-D]PYRIMIDINE
• Synonyms: 2,4-DICHLOROFURO[3,2-D]PYRIMIDINE;2,4-Dichlorofuro[3,2-d]py...;4-dichlorofuro[3;Furo[3,2-d]pyrimidine, 2,4-dichloro-
• CAS NO: 956034-07-4
• Molecular Formula: C₆H₂Cl₂N₂O
• Molecular Weight: 189
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Heterocycle-Pyrimidine series
• Mol File: 956034-07-4.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 1.619 g/cm³
• Refractive Index: 1.646
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.02±0.40(Predicted)
• CAS DataBase Reference: 2,4-DICHLOROFURO[3,2-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLOROFURO[3,2-D]PYRIMIDINE(956034-07-4)
• EPA Substance Registry System: 2,4-DICHLOROFURO[3,2-D]PYRIMIDINE(956034-07-4)

Safety Data

• Hazardous Substances Data: 956034-07-4(Hazardous Substances Data)

Usage

Uses

2,4-Dichlorofuro[3,2-d]pyrimidine is a furopyrimidine derivative used in the preparation of phosphoinositide 3-kinase inhibitor.

InChI:InChI=1/C6H2Cl2N2O/c7-5-4-3(1-2-11-4)9-6(8)10-5/h1-2H

Upstream product

• 956034-06-3 furo[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 956034-06-3 furo[3,2-d]pyrimidine-2,4-diol 
• 1093066-63-7 methyl 3-ureidofuran-2-carboxylate 
• 956034-04-1 methyl 3-aminofuran-2-carboxylate 
• 956034-03-0 methyl 3-((tert-butoxycarbonyl)amino)furan-2-carboxylate 

Downstream Products

• 956034-08-5 2-chloro-4-morpholinofuro[3,2-d]pyrimidine 
• 1312929-43-3 methyl 3-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxylate 
• 1312929-40-0 3-(2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxylic acid 
• 1312929-29-5 N-cyclobutyl-3-(2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide 
• 1312929-44-4 sodium 3-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxylate 
• 1312929-45-5 (S)-3-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxylic acid 
• 1312929-31-9 (S)-N-cyclopropyl-3-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide 
• 1312929-46-6 3-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-N-(3-methoxyphenyl)-1H-pyrazole-5-carboxamide 
• 1312929-26-2 N-(3-methoxyphenyl)-3-(2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide 
• 1312929-47-7 3-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxylic acid 
• 1312929-48-8 3-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-N-(pyridin-4-yl)-1H-pyrazole-5-carboxamide 
• 1312929-27-3 3-(2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-ylamino)-N-(pyridin-4-yl)-1H-pyrazole-5-carboxamide 
• 1312929-34-2 5-(2-chlorofuro[3,2-d]pyrimidin-4-ylamino)-N-cyclopropyl-1H-pyrazole-3-carboxamide 
• 1312929-33-1 3-amino-1-(2-chlorofuro[3,2-d]pyrimidin-4-yl)-N-cyclopropyl-1H-pyrazole-5-carboxamide 

Relevant articles and documents

PARP-1/PI3K double-target inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof

The invention discloses a PARP-1/PI3K double-target inhibitor or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. According to the invention, the single active component can play a dual inhibition role on PARP-1 and PI3K, so that the dosage is reduced, the treatment effect is improved, and the toxic and side effects are reduced; and the dual inhibition effect on PARP-1 and PI3K is significant, the IC50 value of each target does not exceed 1.0 [mu]M, and the drug using the PARP-1/PI3K double-target inhibitor as the active component can be used for treating a variety of cancers or tumors related to PARP-1 and/or PI3K.

Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives

The invention belongs to the field of drug synthesis and relates to novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, preparation methods of thenovel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof and use of the novel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of therapeutic agents, particularly PAK inhibitors. The derivatives disclosed by the invention are represented by a general formula (I) or (II), wherein each substituent is as defined in claims.

Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors

G9a is a histone lysine methyltransferase (HKMT) involved in epigenetic regulation via the installation of histone methylation marks. 6,7-Dimethoxyquinazoline analogues, such as BIX-01294, are established as potent, substrate competitive inhibitors of G9a. With an objective to identify novel chemotypes for substrate competitive inhibitors of G9a, we have designed and synthesised a range of heterocyclic scaffolds, and investigated their ability to inhibit G9a. These studies have led to improved understanding of the key pharmacophoric features of BIX-01294 and the identification of a new core quinoline inhibitory scaffold, which retains excellent potency and high selectivity. Molecular docking was carried out to explain the observed in vitro data. This journal is